ACTA1 and COVID-19: The COVID-19 samples presented statistically increased tissue immunoexpression of ACE-2 (p < 0.0001), AKT-1 (p = 0.022), CD44v6 (p < 0.0001), IL-4 (p < 0.0001), MMP-9 (p = 0.004), α-SMA (p < 0.0001), Sphingosine-1 (p < 0.0001), and TGF-β1 (p = 0.0315) when compared to the CONTROL group.